Antinociception induced by rosuvastatin in murine neuropathic pain

Hugo F. Miranda, Fernando Sierralta, Nicolas Aranda, Paula Poblete, Rodrigo L. Castillo, Viviana Noriega, Juan Carlos Prieto

Resultado de la investigación: Article

Resumen

Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.

Idioma originalEnglish
Páginas (desde-hasta)503-508
Número de páginas6
PublicaciónPharmacological Reports
Volumen70
N.º3
DOI
EstadoPublished - 1 jun 2018

Huella dactilar

Neuralgia
Sciatic Nerve
Paclitaxel
Ligation
Interleukin-1
Glutathione
Spinal Cord
Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glutathione Disulfide
Peripheral Nervous System Diseases
Neuroglia
Lipid Peroxidation
Rosuvastatin Calcium
Anti-Inflammatory Agents
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Citar esto

Miranda, H. F., Sierralta, F., Aranda, N., Poblete, P., Castillo, R. L., Noriega, V., & Prieto, J. C. (2018). Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacological Reports, 70(3), 503-508. https://doi.org/10.1016/j.pharep.2017.11.012
Miranda, Hugo F. ; Sierralta, Fernando ; Aranda, Nicolas ; Poblete, Paula ; Castillo, Rodrigo L. ; Noriega, Viviana ; Prieto, Juan Carlos. / Antinociception induced by rosuvastatin in murine neuropathic pain. En: Pharmacological Reports. 2018 ; Vol. 70, N.º 3. pp. 503-508.
@article{e84f23bd26de4c7daf28870054ef3908,
title = "Antinociception induced by rosuvastatin in murine neuropathic pain",
abstract = "Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.",
keywords = "Antinociception, Neuropathy, Rosuvastatin, Spinal cord biomarkers",
author = "Miranda, {Hugo F.} and Fernando Sierralta and Nicolas Aranda and Paula Poblete and Castillo, {Rodrigo L.} and Viviana Noriega and Prieto, {Juan Carlos}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.pharep.2017.11.012",
language = "English",
volume = "70",
pages = "503--508",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "3",

}

Miranda, HF, Sierralta, F, Aranda, N, Poblete, P, Castillo, RL, Noriega, V & Prieto, JC 2018, 'Antinociception induced by rosuvastatin in murine neuropathic pain', Pharmacological Reports, vol. 70, n.º 3, pp. 503-508. https://doi.org/10.1016/j.pharep.2017.11.012

Antinociception induced by rosuvastatin in murine neuropathic pain. / Miranda, Hugo F.; Sierralta, Fernando; Aranda, Nicolas; Poblete, Paula; Castillo, Rodrigo L.; Noriega, Viviana; Prieto, Juan Carlos.

En: Pharmacological Reports, Vol. 70, N.º 3, 01.06.2018, p. 503-508.

Resultado de la investigación: Article

TY - JOUR

T1 - Antinociception induced by rosuvastatin in murine neuropathic pain

AU - Miranda, Hugo F.

AU - Sierralta, Fernando

AU - Aranda, Nicolas

AU - Poblete, Paula

AU - Castillo, Rodrigo L.

AU - Noriega, Viviana

AU - Prieto, Juan Carlos

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.

AB - Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.

KW - Antinociception

KW - Neuropathy

KW - Rosuvastatin

KW - Spinal cord biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85045249401&partnerID=8YFLogxK

U2 - 10.1016/j.pharep.2017.11.012

DO - 10.1016/j.pharep.2017.11.012

M3 - Article

AN - SCOPUS:85045249401

VL - 70

SP - 503

EP - 508

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 3

ER -

Miranda HF, Sierralta F, Aranda N, Poblete P, Castillo RL, Noriega V y otros. Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacological Reports. 2018 jun 1;70(3):503-508. https://doi.org/10.1016/j.pharep.2017.11.012